Detection of Potential Metabolic and Alcohol–Associated Liver Disease and Alcohol-Associated Liver Disease Using Phosphatidylethanol in a Large Multicenter Metabolic Dysfunction–Associated Steatohepatitis Trial Screening Cohort
Clinical Gastroenterology and Hepatology · 2026-08
DOI: 10.1016/j.cgh.2026.08.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-08. Verfasst von Mazen Noureddin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Sherrie and Alan Conover Center for Liver Disease and Transplantation, JC Walter Jr Transplant Center, Houston Methodist Hosp…. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND & AIMS: Accurate distinction between metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and the overlap metabolic and alcohol-associated liver disease (MetALD) is of utmost importance. Due to the potential for underreporting in alcohol use surveys, phosphatidylethanol (PEth) is increasingly utilized in clinical trials to rule out MetALD or ALD. This study examines the prevalence of elevated PEth and its effectiveness in separating phenotypes with dominant MASLD, MetALD, or ALD in the clinical trial setting. METHODS: A multicenter database of patients screened for enrollment in clinical trials for MASLD pharmacologic therapies was reviewed, from which patients with PEth results were identified, then further stratified into low (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Sherrie and Alan Conover Center for Liver Disease and Transplantation, JC Walter Jr Transplant Center, Houston Methodist Hospital, Houston, Texas; Houston Research Institute, Houston, Texas. Elec…
- Department of Medicine, Saarland University Medical Center, University of the Saarland, Homburg, Germany.
- Pinnacle Clinical Research, San Antonio, Texas.
- Summit Clinical Research, San Antonio, Texas.
- Centro de Investigacion y Gastroenterologia, Ciudad de Mexico, Mexico.
- South Denver Gastroenterology, Englewood, Colorado.
Zitieren
APA
Noureddin, M., Schattenberg, J. M., Patil, R., Brombosz, E. W., Binkauskiene, G., Mazuranic, M., Ladron de Guevara Cetina, L., Kugelmas, M., Sheikh, A., Poulos, J., Kodali, S., Lee, B. P., Arab, J. P., & Alkhouri, N. (2026). Detection of Potential Metabolic and Alcohol–Associated Liver Disease and Alcohol-Associated Liver Disease Using Phosphatidylethanol in a Large Multicenter Metabolic Dysfunction–Associated Steatohepatitis Trial Screening Cohort. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.08.011
Vancouver
Noureddin M, Schattenberg JM, Patil R, Brombosz EW, Binkauskiene G, Mazuranic M, et al. Detection of Potential Metabolic and Alcohol–Associated Liver Disease and Alcohol-Associated Liver Disease Using Phosphatidylethanol in a Large Multicenter Metabolic Dysfunction–Associated Steatohepatitis Trial Screening Cohort. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.08.011
BibTeX
@article{Noureddin2026,
author = {Noureddin, Mazen and Schattenberg, Jörn M and Patil, Rashmee and Brombosz, Elizabeth W and Binkauskiene, Gražina and Mazuranic, Michelle and Ladron de Guevara Cetina, Laura and Kugelmas, Marcelo and Sheikh, Aasim and Poulos, John and Kodali, Sudha and Lee, Brian P and Arab, Juan Pablo and Alkhouri, Naim},
title = {Detection of Potential Metabolic and Alcohol–Associated Liver Disease and Alcohol-Associated Liver Disease Using Phosphatidylethanol in a Large Multicenter Metabolic Dysfunction–Associated Steatohepatitis Trial Screening Cohort},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
doi = {10.1016/j.cgh.2026.08.011}
}
EUVIMED